Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2023-11-15 00:00:00 ET · period of report 2023-11-14 · accession 0001867096-23-000143 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-11-15 | 2023-11-14 | XERS | PERSKY MARLA | Dir | P - Purchase | $1.58 | +6,370 | 6,370 | New | +$10.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-14 | P | A | 6,370 | $1.58 | 6,370 | I By: Marla Susan Persky Revocable Trust u/a dated 9/23/2000 | — | — | (F1) The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |